License Agreement Milestone, Development, Total Payments

No definition available.

Name:	immu_LicenseAgreementMilestoneDevelopmentTotalPayments
Namespace Prefix:	immu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License Agreement Milestone, Payment Upon Achievement of FDA Approval

+ References

No definition available.

+ Details

Name:	immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval
Namespace Prefix:	immu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License Agreement Milestone, Sales, Total Payments

+ References

No definition available.

+ Details

Name:	immu_LicenseAgreementMilestoneSalesTotalPayments
Namespace Prefix:	immu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License Agreement, Upfront Fees Paid

+ References

No definition available.

+ Details

Name:	immu_LicenseAgreementUpfrontFeesPaid
Namespace Prefix:	immu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalty Payments, Percentage

+ References

No definition available.

+ Details

Name:	immu_RoyaltyPaymentsPercentage
Namespace Prefix:	immu_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_MajorCustomersAxis=immu_EverestMedicinesIILimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_MajorCustomersAxis=immu_JanssenBiotechInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue Recognition - Additional Information (Details) - USD ($)			3 Months Ended	6 Months Ended
	Apr. 29, 2019	Apr. 05, 2019	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred revenues			$ 65,000,000	$ 65,000,000	$ 0
Everest Medicines II Limited
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Upfront fees paid	$ 65,000,000.0
Milestone payment, achievement of FDA approval for sacituzumab govitecan	60,000,000.0
Milestone payment, sales	530,000,000.0
Remaining performance obligation	65,000,000.0
Deferred revenues	$ 65,000,000.0
Everest Medicines II Limited \| Minimum
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Royalty payments	14.00%
Everest Medicines II Limited \| Maximum
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Milestone payment, development	$ 180,000,000.0
Royalty payments	20.00%
Janssen Biotech Inc.
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Milestone payment, sales		$ 15,000,000.0
Revenues			$ 0	$ 0